Dr. Iya Khalil has had a storied career at the intersection of tech and medicine. The founder and CEO of GNS Healthcare left that position after a decade to join Microsoft’s Novartis in 2020.
Now, Dr. Kahlil is moving on again. She will join pharma giant Merck as Vice President and Head of Data, AI and Genome Sciences.
A near-death experience
Khalil’s journey in medicine was nearly cut short in 2011, when she suffered a sudden embolism. Though she was already a giant in her field, this strengthened and altered her perspective.
“As physicists, we predicted the existence of the Higgs-Boson decades before we verified experimentally, we made this prediction via mathematical equations,” thought Khalil. “So why can’t we do this for our own health?” This question pushed her career towards computational biology.
Dr. Iya Khalil merges tech and medicine
In 2000, Dr. Khalil founded a state-of-the-art tech science company which would later become GNS. After a decade at the helm, she then moved on to Microsoft, and now to Merck.
In 2014, Khalil was recognized by President Obama as a leading entrepreneur in her field. Khalil also supports female entrepreneurs, co-founding the nonprofit initiative Female Equity.
Across her work, Khalil has made a point to merge the latest in technological advancements with the modern medicine. Using AI, machine learning, and other tools, she has made incredible strides in health and medicine.
Learn more about Dr. Iya Khalil here.
